首页> 外文期刊>International journal of immunopathology and pharmacology. >Helicobacter pylori therapy in children: Overview and challenges
【24h】

Helicobacter pylori therapy in children: Overview and challenges

机译:儿童幽门螺杆菌治疗:概述和挑战

获取原文
获取原文并翻译 | 示例
           

摘要

Helicobacter pylori is one of the most common infections found in humans. It was first identified in 1982 and by 1989 had been associated with gastric inflammation and ulcers in adults and children. During the 1990's evidence emerged of its etiologic role in stomach cancers in adults. That the infection is common and may have serious consequences, has led to an avalanche of research during the last twenty years. During this time, there have been many studies on children which have sought an effective and safe treatment to eradicate the infection, but as yet, no therapy regimen has been found which is always effective and safe. This article provides information, from a pediatric point of view, on the major developments in the therapeutics and therapy of H. pylori infection. It examines first-line treatment regimens, evaluates the efficacy of the main drugs used in the management of (primary) H. pylori infection in children, assesses the potential for the use of probiotics and sequential therapy, examines therapeutic options after failure of initial treatment, and discusses factors affecting eradication rate, including antibiotic resistance, adherence to therapy, and bacterial factors.
机译:幽门螺杆菌是人类发现的最常见的感染之一。它于1982年首次发现,到1989年已与成人和儿童的胃部炎症和溃疡相关。在1990年代,有证据表明其在成人胃癌中的病因学作用。在过去的二十年中,这种感染很普遍并且可能造成严重后果,导致了雪崩的研究。在这段时间内,已经有许多关于儿童的研究,他们寻求一种有效,安全的治疗方法来根除感染,但至今仍未找到始终有效且安全的治疗方案。本文从儿科的角度提供了有关幽门螺杆菌感染的治疗和发展方面的主要信息。它检查一线治疗方案,评估用于治疗儿童(原发性)幽门螺杆菌感染的主要药物的功效,评估使用益生菌和序贯疗法的潜力,在初始治疗失败后检查治疗方案,并讨论了影响根除率的因素,包括抗生素耐药性,治疗依从性和细菌因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号